Regis Technologies
IAM Drugs Discovery Phase
IAM.PC / IAM.PC.MG
The IAM.PC phase, developed by Dr. Charles Pidgeon of Purdue University, was the first in a line of IAM phases to be manufactured by Regis. Use of this phase has simplified the inherent difficulties of protein isolation and purification, allowing for rapid purification of membrane proteins while maintaining biological activity. The IAM.PC phase is an important tool for the pharmaceutical industry and academia alike.
The first IAM stationary phase was based on the prevalent membrane lipid, phosphatidylcholine (PC), and consists of monolayers of amphiphilic phospholipids covalently bonded to aminopropyl silica particles through a terminal amide linkage. As a result, the bulky phosphatidylcholine groups shield many of the amine binding sites on the silica surface, preventing amine interaction with the protein molecules. (Figure 1)
The membrane nature of the IAM phase imparts surface characteristics which are useful in the chromatography of membrane proteins. These include: high protein loading, increased protein recovery, recovery of functional activity, and selectivity for membrane proteins.
Large membrane proteins can interact with any combination of polar headgroup, hydrophobic chain, or inner amine groups. The subsurface has been shown to interact with certain solutes, and may or may not contribute to the separation of a given biomolecule. The residual amines can be left unaltered on the subsurface or deactivated through an endcapping procedure, which results in increased stability of the bonded phase. The methyl glycolate endcapping, for example, converts residual amines to neutral amides and introduces a hydroxyl group (IAM.PC.MG).
IAM.PC Applications
Numerous applications have been developed using IAM.PC columns:
-
Purification of Cytochrome P450
-
Isolation of membrane proteins
-
Prediction of solute transport across human skin
-
Prediction of amino acid transport across the blood-brain barrier
-
Binding of solutes to liposome membranes
-
Immobilization of Trypsin and α-chymotrypsin for the determination of their inhibitor and substrate activity
For additional information on IAM.PC applications please contact us.
Products
| Product | Particle Size | Column Dimensions | Product Code |
| IAM.PC | 10 µm, 300Å | 15 cm x 4.6 mm i.d. | 770001 |
| IAM.PC | 10 µm, 300Å | 3 cm x 4.6 mm i.d. | 770007 |
| IAM.PC Guard Cartridges | 10 µm, 300Å | 1 cm x 3.0 mm i.d. | 774001 |
| IAM.PC Guard Kit | 10 µm, 300Å | 1 cm x 3.0 mm i.d. | 771001 |
| IAM.PC.MG | 10 µm, 300Å | 15 cm x 4.6 mm i.d. | 772001 |
| IAM.PC.MG | 10 µm, 300Å | 3 cm x 4.6 mm i.d. | 772007 |
| IAM.PC.MG Guard Cartridges | 10 µm, 300Å | 1 cm x 3.0 mm i.d. | 775001 |
| IAM.PC.MG Guard Kit | 10 µm, 300Å | 1 cm x 3.0 mm i.d. | 773001 |